A polymer-(tandem drugs) conjugate for enhanced cancer treatment.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23296686.
- Also identified by DOI 10.1002/adhm.201200385.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A novel strategy for combination chemotherapy (platinum and demethylcantharidin) via a polymer-(tandem drugs) conjugate for enhanced cancer treatment is demonstrated. Cisplatin can be released inside cell by reduction to attack DNA, while DMC will be hydrolyzed subsequently to block DNA-damage-induced defense mechanisms by serine/threonine phosphatase PP2A inhibition. Synergistic effect of the polymer-(tandem drugs) conjugate causes complete suppression of H22 liver tumor xenografts without recurrence.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Cantharidin
- Liver Neoplasms
- Nanocapsules
- Platinum
- Polymers